Johnson & Johnson Depression

FDA-Approved Nasal Spray For Depression Is 1st Of Its Kind

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

Fox Business · 3d

J&J's ketamine-derived nasal spray approved by FDA to treat depression

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

CNN on MSN · 3d

FDA approves standalone use of J&J’s ketamine-derived depression treatment

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.

1don MSN

Nasal spray approved to help treat depression

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

BioSpace1d

J&J Says Deals Likely to Shrink After $14.6B Intra-Cellular Buy

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

Pregnancy raises risks to mental health in MS patients, study says

Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.

21hon MSN

Johnson & Johnson's SWOT analysis: oncology portfolio drives growth amid challenges

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results